Recombinant canine interferon-ã (KT-100) or topical antihistamine (diphenhydramine: DH) was administered to dogs with atopic dermatitis (AD) for 4 weeks and their efficacies were compared using pruritus, excoriation, erythema and alopecia as evaluation criteria.
Clinical studies on 92 atopic dogs (KT-100 group: 63, DH group: 29) were conducted at 18 animal hospitals in Japan.
KT-100 was administered subcutaneously once a day three times a week on alternating days for 4 weeks.
DH was administered topically twice daily for 4 weeks.
The efficacy rates of the KT-100 group on day 28 were 72.1% for pruritus, 73.8% for excoriation, 75.4% for erythema and 60.7% for alopecia, which were significantly higher than those of the DH group (20.7% for pruritus, 27.6% for excoriation, 24.1% for erythema and 24.1% for alopecia).
Source: Iwasaki, Toshiroh & Hasegawa, Atsuhiko (2006): A randomized comparative clinical trial of recombinant canine interferon-ã (KT-100) in atopic dogs using antihistamine as control. In: Veterinary Dermatology 17 (3), 195-200.
Tell a friend
|
Print version
|
Send this article
|
